Volume 7, Issue 1, February 2003  


What’s inside . . .

Message From the Coordinator


Message From the Editor


News and Updates


News From the National Human Genome Research Institute


Myriad Genetics Laboratories Gives Report on 10,000 Consecutive Clinical Genetic Tests


SIG Officers    Click here to print this newsletter


Message From the Coordinator
SIG on the Forefront of Promoting Genetics in Oncology

Agnes Masny, RN, MPH, MSN, CRNP
Philadelphia, PA
ac_masny@fccc.edu


The year 2003 holds great promise for cancer care. In April, the sequencing of the human genome will be complete. In addition, April will mark the 50th anniversary of James Watson's and Francis Crick's description of the DNA double helix. With these events, we will move from a “medical era” to the “genomic era.” Genomics is expected to revolutionize the way oncology care is delivered. Although most nurses in the Cancer Genetics SIG work in the area of cancer risk assessment and counseling, we will be on the forefront helping other nurses apply genetics to oncology practice. This coming year, the SIG will work to better our networking and resources. Lisa Aiello, RN, MSN, will continue to work as page administrator for our virtual community site. Please visit the site or send information to Lisa if you want something posted. Marty Weinar, RN, MS, CCRC, is compiling a genetics bibliography to be published in a 2003 issue of the Oncology Nursing Forum.

In this newsletter, Jean Jenkins, PhD, RN, FAAN, has provided an update of activities and resources from the NHGRI. We also have contacted the Cancer Genetics SIG from the National Society of Genetic Counselors to create a liaison between our SIGs and to work on a common project. To ready the larger ONS membership for the genomics era, the SIG will mark the 50th anniversary of DNA at Congress with a DNA celebration. This event is still in the planning phase. If you would like to help on any of these projects, please call or e-mail me (see SIG Officers page for contact information). Each of us can help the SIG or other oncology nurses learn more about genetics, no matter how small our attempts. Every effort will keep the SIG vital.

Back to top



Special Interest Group Newsletter  February 2003

Message From the Editor
SIG Seeks Volunteers for Publication

Judie Much, RN, MSN, APN-C, AOCN®
Ottsville, PA
muchjk@umdnj.edu


Help! Help! Help! We need you! As this newsletter goes into final production, the realization begins to sink in that this will be our first online edition! We hope you will enjoy the electronic access to the information. We continue to need volunteers to review research articles for the publication, as well as to provide news clips and items of interest to the membership. We are looking for co-editors in various regions. Are you planning to go to Congress this year? Do you have a “hot topic” to submit to the SIG for a Congress session? We hope so, and we encourage you to come prepared to present your ideas at the SIG networking meeting. As we only meet once a year, it is very important to bring ideas with you so that we can make the most of our short time together. We hope you will come and spend time “around the table” and get to know those in your SIG. Look for information in the mail and on the virtual community for specifics about related activities at Congress, including the location and time of the SIG networking meetings.


Back to SIG Newsletter front page



Special Interest Group Newsletter  February 2003

News and Updates
Summer Genetics Institute
The National Institutes of Nursing Research will sponsor the Summer Genetics Institute from June 1-July 25 at the National Institutes of Health. The Institute is designed to provide a foundation in genetics for use in research and clinical practice. The purpose is to develop and expand the research capability among graduate students and faculty in schools of nursing and to develop and expand the basis for clinical practice in genetics among advanced practice nurses. More information, as well as the application process, can be found at http://www.nih.gov/ninr/research/dir/sgi.html, or you can write Summer Genetics Institute, National Institute of Nursing Research, 31 Center Drive, Room 5B-13, Bethesda, MD 20892-2718.

SIG Members Edit Genetic Text
The new text Genetics in Oncology Practice: Cancer Risk Assessment, edited by our own Amy Strauss Tranin, ARNP, MS, AOCN®, Agnes Masny, RN, MPH, MSN, CRNP, and Jean Jenkins, PhD, RN, FAAN, is now available for purchase through ONS's Publishing Division. The book is a “must have” for anyone practicing in the field, as well as for those who are considering starting a cancer risk assessment clinic. Check ONS Online (www.ons.org) for a 20% discount!

SIG Member Joins Staff of NHGRI
The National Human Genome Research Institute (NHGRI) has named Jean Jenkins, PhD, RN, FAAN, as senior clinical advisor. Jenkins will continue NHGRI’s mission of educating healthcare professionals and the public about the role of genetic medicine in the clinic, as well as the health and societal implications of the Human Genome Project.


Back to SIG Newsletter front page




Special Interest Group Newsletter  February 2003

News From the National Human Genome Research Institute

Jean Jenkins PhD, RN, FAAN
Bethesda, MD
Jean.Jenkins@nih.gov


There were a lot of 2002 NHGRI activities with potential implications for nurses, and there are several 2003 events that you may want to participate in. You can find out more about each of the topics highlighted below by visiting the newly revamped NHGRI Web site at genome.gov.

  • Planning the NHGRI’s Future—A Vision for the Future of Genomics
    It is projected that by 2003, all of the Human Genome Project goals, as outlined in Science (1998), will be accomplished and the genome sequence will be completed. NHGRI is in the process of gathering information that will provide the basis of setting an agenda for the future of genomics, in general, and the focus of the NHGRI, in particular. Multiple workshops have examined the current status of technology, clinical research, and research into the ethical, legal, and social implications (ELSI) of genetics. Results from this planning process provide the backbone to the development of recommendations for a new NHGRI research plan. (See workshop summary information at the NHGRI Web site in the newsroom planning area). This new plan, to be published in April, has major implications for all healthcare providers, including nurses, as it is already clear that bringing the benefits of genomics to health care will be a major focus of NHGRI’s new plan. Click here to view portions of the meeting via Web cast.

  • A Celebration of the Genome—50 Years of DNA: From Double Helix to Health
    Several publications, social events, and educational symposiums in April will highlight genetic accomplishments. See more about some of these by going to the NHGRI 50 Years of DNA Web site. We invite you to see this as an opportunity for nurses to highlight their contributions! In fact, please contact me if you would like to share your ideas or if you think NHGRI might be able to be of help with them (Jean.Jenkins@nih.gov). One event, sponsored by the National Institute of Nursing Research, will focus on implications of genetics for nursing research. Visit www.nih.gov/ninr for more information.

    Other events will include museum exhibits across the country and a series of educational events, including schools marking the 50th anniversary of the description of the double helix on April 25: “National DNA Day.” Also, there will be an extraordinary scientific symposium at NHGRI on April 14-15 that will be Web cast nationally. It will feature James Watson, Francis Collins, and others discussing the past, present, and future of genetics and genomics. There also will be a public symposium at the Smithsonian’s National Museum of Natural History on the morning of April 15.

  • An Educational Resource
    A User’s Guide to the Human Genome was published in September 2002 by Nature. This resource also is available electronically.

  • International HapMap Project
    An international research consortium announced an ambitious initiative to complete within three years—a genetic variation mapping project. The HapMap Project seeks to provide a tool that speeds the discovery of the identification of disease-related genes for common illnesses. Researchers will be sampling populations to identify genetic variation in significant haplotype blocks. Informed consent, privacy issues, and genetic determinism assumptions are a few of the recognized potential problems of such research.

  • Mentorship Program
    NHGRI and the American Society of Human Genetics are offering a Web-based mentorship program on genetics to high school teachers. To date, more than 700 volunteers have signed onto the program, including geneticists, lab personnel, and genetic counselors. This mentorship network also will participate in some of the April events mentioned above.

  • National Coalition for Healthcare Professional Education in Genetics (NCHPEG) and Genetics Resources on the Web
    NHGRI and the Health Resources Services Administration recently awarded a contract to NCHPEG that will support efforts to promote education for healthcare professionals and access to information about advances in human genetics. Many professional nursing organizations have representatives to this coalition. Visit www.nchpeg.org to see if your organization participates.

  • Genetics Series
    The New England Journal of Medicine began a year-long series of monthly articles on genomics. The articles will focus on the "academically oriented clinician" and attempt to relate the genetics that such a person would be able to use and, thus, need to know today. As they are published, the articles in this Genomic Medicine Series will be available without charge at www.nejm.org.

Several of the highlighted topics offer an opportunity for improved nursing visibility in the advancement of genetics into education and clinical practice. Share your expertise with others, and all will benefit because of your efforts.


Back to SIG Newsletter front page




Special Interest Group Newsletter  February 2003

Review
Myriad Genetics Laboratories Gives Report on 10,000 Consecutive Clinical Genetic Tests

Judie Much, RN, MSN, APN-C, AOCN®
muchjk@umdnj.edu


Alterations in BRCA1 and BRCA2 originally were found in large families enriched with disease. Clinically, it has been felt for some time that these families are not typical of the majority of families believed to be at risk and who, subsequently, test positive in clinical settings throughout the country. In spite of the fact that testing has been available since 1996, controversy continues to exist regarding the specific features (both family and personal) that should prompt the offering of testing. Some of that controversy involves whether to include ductal carcinoma in situ (DCIS) in the spectrum of consideration when assessing “affected” relatives in a family history and whether male breast cancer is part of the spectrum of disease in either BRCA1 or BRCA2. Also unclear has been the characterization of the spectrum of disease and its prevalence in particular populations, such as African Americans, Ashkenazi Jews, and other ancestries.

In an attempt to clarify these issues, Myriad Genetic Laboratories, which has been testing individuals based on their personal and family histories since 1996, looked retrospectively at 10,000 consecutive tests performed by their laboratory (Frank et al., 2002). These were either full sequencing of 17,500 base pairs of the protein-coding and adjacent noncoding regions of the BRCA1 and BRCA2 genes or sequence analysis for the three specific founder mutations prevalent in Ashkenazi Jews. This was an attempt to correlate the presence of mutations with the personal and family histories in order to help clarify the issues mentioned earlier. It is important to note that information regarding family history was not confirmed but was simply a reflection of the information provided on the test request form filled out by the requesting healthcare provider. Individuals were considered to have no history only if the requisition form indicated “none” in the family history section. If there was no information included in the section, the sample was not included in the analysis.

Population
Ten thousand samples collected consecutively over a three-year period were included. Approximately 7,500 samples were analyzed by full sequencing. Twenty five hundred were analyzed for the three founder mutations in the Ashkenazi Jewish population. Of the 10,000 analyzed, more than 9,000 were women, more than 260 men, and 650 did not specify sex. Median age was 49. Approximately 5,500 individuals had a personal history of breast or ovarian cancer, including 4,679 with breast cancer (76 males), 584 with ovarian cancer, and 240 with both. Of those affected with breast cancer, the median age was 44. The median age in those with ovarian cancer was 53. Ancestry was characterized as “Northern/Western Europe” in 41%, Ashkenazi 30%, no designation 18%, and a small percentage of “others.”

Results
Results were reported in one of three categories: 1) positive for a deleterious mutation, 2) genetic variant of uncertain significance, or 3) no deleterious mutation detected. More than 1,700 individuals had mutations identified (17.2%), and 11 Ashkenazi Jews had two mutations identified, one in each gene. Mutations occurred in 15.7% of individuals who reported non-Ashkenazi Jewish ancestry and in 20.4% of Ashkenazi Jews. Sixty one percent of the mutations occurred in BRCA1, whereas BRCA2 accounted for 39%. There were 212 deleterious mutations each in BRCA1 and BRCA2. Of those, 60% were frameshift mutations, 25% were nonsense, 9% were missence, and 12.5% occurred in the analyzed regions of the noncoding introns. In individuals who had full sequence testing performed, 13% had variants of uncertain clinical significance, and an additional 6.8% had variants that had at one time been classified as of uncertain significance and had since been reported as polymorphisms. Of the Ashkenazi Jews tested for the founder mutations, 53% had mutations in BRCA1 187delAG, 16% had mutations in BRCA1 5385insC, and 31% had a mutation in BRCA2 6174delT.

Of the nearly 5,000 women in the sample with breast cancer, 20% carried deleterious mutations, approximately two-thirds of which were in BRCA1. Median age of diagnosis was 40 for those with BRCA1 mutations and 41 for those with BRCA2 mutations.

Of the more than 800 women with ovarian cancer, 34% carried deleterious mutations, with two-thirds presenting in BRCA1. Median age for development of ovarian cancer was 49 and 55 in those with mutations in BRCA1 and BRCA2, respectively. Deleterious mutations were found in approximately 10% of women with no personal history of breast or ovarian cancer.

In non-Ashkenazi Jews tested, the highest prevalence of mutations was seen when a proband’s personal and family history included women diagnosed with breast cancer before the age of 50 along with ovarian cancer at any age. Mutations also were prevalent in families without ovarian cancer if there were at least two women with early-age breast cancer. Tables in the body of the paper reveal the earlier the onset of breast cancer, the more likely one is to find a mutation. Most notable was the prevalence rate of mutation in a woman younger than 50 with a personal history of breast cancer and no other family history (9.5%). This same age correlation was not found with ovarian cancer. That is to say that the diagnosis of ovarian cancer alone in these families is sufficient to increase the prevalence rate of mutation status. Age was not a factor.

In Ashkenazi individuals, mutation status was correlated with early onset of breast or ovarian cancer as well as younger age of onset of breast cancer in the proband. Ashkenazi Jewish women diagnosed with breast cancer prior to age 50 (12.9%) were found to have mutations even in the absence of a “family history.” Having ovarian cancer raised the proportion to 25.9%, and if one had both breast and ovarian cancer and was Ashkenazi, the prevalence reached 52%. Of the mutations found in Ashkenazi Jews who had full sequencing, 12.6% of these mutations were nonfounder mutations. In those Ashkenazi Jews with a compelling family history of breast cancer prior to age 50 or ovarian cancer at any age, nonfounder mutations were seen in only 4.7% of individuals, as compared with 31.3% of individuals with similar family history who were non-Ashkenazi. Several recurrent missense mutations, thought to be of little clinical consequence, were found in the Ashkenazi population at a prevalence rate of about 5%: BRCA1 variant M10081 and BRCA2 variants P655R and I2285V.

In individuals who specified only a single ancestral line, mutations were found in 21% of Ashkenazi Jews, 19% of African Americans, 18% of Latin Americans/Carribeans, 14% of Native Americans, 12% of Asians, and 9% of Near Eastern/Middle Eastern ancestry.

In women with DCIS, mutations were found less frequently than in women with invasive cancers: 13% versus 24%, respectively (excluding women also diagnosed with ovarian cancer). Males diagnosed with breast cancer had a prevalence rate of mutation of 28%. These occurred in both BRCA1 and BRCA2. Median age of diagnosis was 52 and 59 for BRCA1 and BRCA2, respectively. Occurrence of the mutations in males was more prevalent when there was a family history of breast or ovarian cancer at any age (36% versus 13%), but this was not statistically significant because of the small numbers in the group.

Discussion
Prevalence rates found in this study, in which family history was “self report” and not confirmed, were similar to more carefully controlled studies where family history was confirmed. However, it is certainly possible that family history was underreported, as healthcare professionals may pick and choose the information they feel is most relevant to include in the family history section of the requisition form. This is a limitation for interpreting the data. Diagnosis of ovarian cancer is much more critical to mutation status than had been previously thought. Unfortunately, family history of ovarian cancer is less likely to be accurate than is family history of breast cancer.

Diagnosis of ovarian cancer after age 50 does not decrease the likelihood that there is a mutation.

None of the Ashkenazi individuals with two mutations had deleterious mutations in the same gene.

As in most series, those with African American ancestry were underrepresented (1.6% of the total). However, the prevalence of mutation in this population with family history is similar to other non-Ashkenazi Jewish groups. If one uses a cutoff for testing of 10% predicted prevalence of a mutation, non-Ashkenazi Jewish women younger than 50 with breast cancer and no other family history should be considered for testing.

Prevalence of mutation status with DCIS needs additional investigation. Mutations in males were equally accounted for by BRCA1 and BRCA2.

The data reported likely underestimate the prevalence of mutations in the clinical setting, as the sequence analysis strategy used renders large insertions/deletions invisible. Such rearrangements reportedly account for about 15% of alterations in BRCA1 and BRCA2.

In summary, mutation status occurs in individuals with relatively unremarkable family histories. In this study, 36% of non-Ashkenazi Jewish families reported a history of only one first- or second-degree relative with early onset breast or ovarian cancer, and of these individuals, 13% were found to have a mutation.

Reference
Frank, T.S., Deffenbaugh, A.M., Reid, J.E., Hulick, M., Ward, B.E., Lingenfelter, B., et al. (2002). Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. Journal of Clinical Oncology, 20, 1480-1490.



Back to SIG Newsletter front page



Special Interest Group Newsletter  February 2003

Cancer Genetics SIG Officers

Coordinator
Agnes Masny, RN, MPH, MSN, CRNP
Fox Chase Cancer Center
7701 Burholme Ave.
Philadelphia, PA 19111-2412
215-728-2892 (O)
215-728-4061 (fax)
ac_masny@fccc.edu

Ex-Officio
Deborah MacDonald, RN, MS, CS, APNG(c)
City of Hope Comprehensive Cancer Center
Clinical Cancer Genetics MOD 103
1500 East Duarte Rd.
Duarte, CA 91010-0269
626-256-6882, ext. 2 (O)
626-930-5495 (fax)
dmacdonald@coh.org

Editor
Judie Much, RN, MSN, APN-C, AOCN®
9027 Easton Rd.
Ottsville, PA 18942-9653
610-847-5402 (H)
732-235-8091 (fax)
muchjk@umdnj.edu
Web Administrator
Lisa Aiello, RN, MSN
136 Hartwell Lane
Philadelphia, PA 19118-3431
215-242-0459 (H)
215-829-6528 (O)
lbaiello@juno.com

Historian
Mary Fraser, RN, MA
National Cancer Institute
Genetic Epidemiology Branch
Executive Plaza North
Room 439 MSC 7372
301-496-4375 (O)
301-402-4489 (fax)
mfraser@nih.gov

ONS Publishing Division Staff
Lori Wilson, BA
Staff Editor
412-859-6288
lwilson@ons.org

Know someone who would like to receive a print copy of this newsletter?
To print a copy of this newsletter from your home or office computer, click here or on the printer icon located on the SIG Newsletter front page. Print copies of each online SIG newsletter also are available through the ONS National Office. To have a copy mailed to you or another SIG member, contact SIGs Administrative Assistant Carol DeMarco at carol@ons.org or 866-257-4ONS, ext. 6230.


The Oncology Nursing Society (ONS) does not assume responsibility for the opinions expressed and information provided by authors or by Special Interest Groups (SIGs). Acceptance of advertising or corporate support does not indicate or imply endorsement of the company or its products by ONS or the SIG. Web sites listed in the SIG newsletters are provided for information only. Hosts are responsible for their own content and availability.

Oncology Nursing Society
125 Enterprise Dr.
Pittsburgh, PA 15275-1214
412-859-6100
ONS Online: www.ons.org


Back to SIG Newsletter front page